Related references
Note: Only part of the references are listed.Rapid Selection of Oseltamivir- and Peramivir-Resistant Pandemic H1N1 Virus during Therapy in 2 Immunocompromised Hosts
Matthew J. Memoli et al.
CLINICAL INFECTIOUS DISEASES (2010)
Pegylated Interferons for the Treatment of Chronic Hepatitis C Pharmacological and Clinical Differences between Peginterferon-alpha-2a and Peginterferon-alpha-2b
Graham R. Foster
DRUGS (2010)
The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities
Michelle Head et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo
Q. M. Nhu et al.
MUCOSAL IMMUNOLOGY (2010)
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa
Aeron C. Hurt et al.
ANTIVIRAL RESEARCH (2009)
Peginterferon-alpha-2a (40 kD) A Review of its Use in Chronic Hepatitis B
Gillian M. Keating
DRUGS (2009)
Costimulation Modulation Uncouples Protection from Immunopathology in Memory T Cell Responses to Influenza Virus
John R. Teijaro et al.
JOURNAL OF IMMUNOLOGY (2009)
The Emergency Use Authorization of Peramivir for Treatment of 2009 H1N1 Influenza
Debra Birnkrant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Global Transmission of Oseltamivir-Resistant Influenza
Anne Moscona
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Emergence of Oseltamivir-Resistant Pandemic H1N1 Virus during Prophylaxis
Mariana Baz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Oseltamivir-Resistant Influenza A Pandemic (H1N1) 2009 Virus, Hong Kong, China
Honglin Chen et al.
EMERGING INFECTIOUS DISEASES (2009)
Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007-08
Siri H. Hauge et al.
EMERGING INFECTIOUS DISEASES (2009)
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients
Jing Li et al.
CLINICAL CANCER RESEARCH (2008)
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response
Akinori Takaoka et al.
NATURE (2007)
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis
Zachary J. Roberts et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Use of neuraminidase inhibitors to combat pandemic influenza
Jane Democratis et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent
M McKeage et al.
CLINICAL CANCER RESEARCH (2006)
Recovery of drug-resistant influenza virus from immunocompromised patients: A case series
MG Ison et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Innate immune recognition of viral infection
T Kawai et al.
NATURE IMMUNOLOGY (2006)
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern
RA Bright et al.
LANCET (2005)
The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis
MG Ottolini et al.
JOURNAL OF GENERAL VIROLOGY (2005)
Drug therapy - Neuraminidase inhibitors for influenza
A Moscona
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Influenza-associated hospitalizations in the United States
WW Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Mortality associated with influenza and respiratory syncytial virus in the United States
WW Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors
JS Oxford et al.
CLINICAL MICROBIOLOGY AND INFECTION (2003)
Medical progress: Multiple sclerosis.
JH Noseworthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
